Year: 2024

Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1) Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with more than 280 subjects enrolled Appointed Hendrik P.N. Scholl, MD, MA, a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest natural history study of Stargardt disease, as Chief Medical Officer Interim analysis from the pivotal global Phase 3 DRAGON trial of Tinlarebant in adolescent STGD1 subjects anticipated by end of 2024 or early 2025 Company to host webcast on Tuesday, November 12, 2024, at 4:30 p.m. ESTSAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development...

Highlights Significantly improved stacking yield.Currently building 5-, 11- and 28-layer batteries on10 µm substrate.Manufacturing volume doubled in Q3 2024, enablingmuch faster learning cycles, and thus the abilityto resolve defect issues at a much faster pace. Weexpect to double manufacturing volume again inQ4 2024.On schedule to implement 24/7 production inQ1 2025 to further ramp up production.Testing multiple materials for final encapsulation andclose to selecting the optimal solution.Pulse rate and charging time have improvedsignificantly compared to original targetspecifications.Cooperating closely with our strategic partners/customers to prepare them for testing our samplebatteries as soon as they are shipped.Exploring new form factors and materials to furtherimprove performance in our next generation ofbatteries,...

Primior Holdings announces Q3 2024 earnings, highlighting advances in property development and tech integration Irvine, California, Nov. 11, 2024 (GLOBE NEWSWIRE) — Primior Holdings Inc. (GRLT) has scheduled its Q3 2024 earnings release, offering shareholders and stakeholders an overview of the company’s performance for the quarter ending September 30, 2024. The report will provide detailed financial data, operational highlights, and updates on strategic initiatives from the third quarter. Primior Holdings Inc.: Innovating real estate with a blend of technology and strategic investment, poised for the Q3 2024 earnings reveal Primior Holdings Inc., emerging from a $30 million merger between GRILLiT Inc. and Primior Inc., has transitioned into a real estate development and investment advisory firm. This merger broadens the...

HOUSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) — VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) (“Vaalco” or the “Company”) today reported operational and financial results for the third quarter of 2024. Third Quarter 2024 Highlights and Recent Key Items:Grew net revenue interest (“NRI”)(2) sales to 2,134,000 barrels of oil equivalent (“BOE”), or 23,198 barrels of oil equivalent per day (“BOEPD”), toward the upper end of guidance; and 20% above the second quarter of 2024 due to additional Côte d’Ivoire liftings; Reported Q3 2024 net income of $11.0 million ($0.10 per diluted share) and Adjusted Net Income(1) of $7.9 million ( $0.08 per diluted share); Increased Adjusted EBITDAX(1) by 28% to $92.8 million compared to Q2 2024, driven by sales increase associated with Côte d’Ivoire liftings; Achieved...